Cancer Research

Positive results in first-in-U.S. trial of CRISPR-edited immune cells

Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.

Penn Today Staff

Blood test can predict prognosis in deadly brain cancer

A Penn study points to clinical utility of liquid biopsy in glioblastoma, allowing doctors the ability to measure the progression of the cancer based on the amount of cell-free DNA in the bloodstream

Penn Today Staff

Basser Center takes aim at BRCA

Twenty-five years after the discovery of genetic mutations that dramatically increase cancer risk, the Penn Medicine’s Basser Center for BRCA is building scientific knowledge alongside public awareness about BRCA-related cancers.

Katherine Unger Baillie



Media Contact


Experts



In the News


HealthDay News

For Breast Cancer Patients, Less Time on Hormonal Meds?

Susan Domchek of the Perelman School of Medicine and the Abramson Cancer Center comments on hormonal therapy.

FULL STORY →



Nature

Acupuncture in Cancer Study Reignites Debate About Controversial Technique

Rollin Gallagher of the Perelman School of Medicine comments on a clinical trial that focused on whether acupuncture can relieve pain in cancer patients.

FULL STORY →